ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA

Clinical trials for ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA trials appear

Sign up with your email to follow new studies for ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

AI steps in: new tool aims to predict who wins against liver cancer

Knowledge-focused Not yet recruiting

This study aims to create an artificial intelligence (AI) tool that can predict how well patients with advanced liver cancer will respond to a specific combination of two drugs. Researchers will look back at the medical records and CT scans of 400 patients who have already receiv…

Matched conditions: ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA

Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused

Last updated Apr 02, 2026 04:26 UTC

ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA

Get alerted when new ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA trials appear

AI steps in: new tool aims to predict who wins against liver cancer